Skip to main content
. 2019 Apr 18;6(12):1900327. doi: 10.1002/advs.201900327

Figure 3.

Figure 3

The combination of PLG‐CA4 and PI3Kγ inhibitor suppresses the growth of orthotopic breast cancer. a) Therapy regimen. b,c) Mean tumor size and body weight of subcutaneous 4T1 tumor in Control, PI3Kγ inhibitor, PLG‐CA4 or PI3Kγ inhibitor combination with PLG‐CA4 (n = 6). d) Change of tumor sizes on day 30 of regime. e) H&E and Ki67 staining of tumor sections on day 30 of therapy regimen (scale bar, 50 µm). Data were presented as means ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.